Total Payments
$171,196
2024 Payments
$3,098
Companies
85
Transactions
1,033
Medicare Patients
4,041
Medicare Billing
$469,370
Payment Breakdown by Category
Other$118,211 (69.1%)
Food & Beverage$21,006 (12.3%)
Consulting$20,620 (12.0%)
Travel$10,528 (6.1%)
Education$485.48 (0.3%)
Research$345.36 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,211 | 64 | 69.1% |
| Food and Beverage | $21,006 | 891 | 12.3% |
| Consulting Fee | $20,620 | 10 | 12.0% |
| Travel and Lodging | $10,528 | 54 | 6.1% |
| Education | $485.48 | 11 | 0.3% |
| Unspecified | $345.36 | 3 | 0.2% |
Payments by Type
General
$170,850
1,030 transactions
Research
$345.36
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $69,323 | 116 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $46,130 | 82 | $0 (2024) |
| ABBVIE INC. | $20,635 | 100 | $0 (2024) |
| Allergan, Inc. | $17,056 | 62 | $0 (2022) |
| EMD Serono, Inc. | $3,036 | 39 | $0 (2024) |
| Genentech USA, Inc. | $2,359 | 44 | $0 (2024) |
| Biogen, Inc. | $1,357 | 71 | $0 (2024) |
| UCB, Inc. | $1,031 | 54 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $790.68 | 46 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $731.05 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,098 | 128 | Alexion Pharmaceuticals, Inc. ($333.88) |
| 2023 | $11,946 | 135 | AbbVie Inc. ($6,754) |
| 2022 | $9,196 | 125 | ABBVIE INC. ($7,176) |
| 2021 | $19,178 | 105 | AbbVie Inc. ($6,227) |
| 2020 | $21,562 | 84 | Allergan, Inc. ($15,006) |
| 2019 | $31,635 | 148 | GENZYME CORPORATION ($21,156) |
| 2018 | $51,048 | 181 | GENZYME CORPORATION ($28,514) |
| 2017 | $23,533 | 127 | Teva Pharmaceuticals USA, Inc. ($11,206) |
All Payment Transactions
1,033 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: PAIN | ||||||
| 12/19/2024 | Alexion Pharmaceuticals, Inc. | — | Education | In-kind items and services | $100.00 | General |
| 12/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: Immune | ||||||
| 12/16/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Neurology | ||||||
| 12/09/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $0.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $0.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: EPILEPSY | ||||||
| 12/04/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Immunology | ||||||
| 11/22/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $23.37 | General |
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Neuropsychiatry | ||||||
| 11/20/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: Central Nervous System | ||||||
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.39 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $119.60 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Neurology | ||||||
| 10/29/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.58 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MS700568-0079 | EMD Serono, Inc. | $261.00 | 1 |
| MS200527-0073 | EMD Serono, Inc. | $84.36 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,027 | 10,695 | $437,420 | $142,340 |
| 2022 | 14 | 837 | 5,939 | $302,939 | $103,220 |
| 2021 | 19 | 1,120 | 5,308 | $366,750 | $128,911 |
| 2020 | 16 | 1,057 | 1,343 | $271,622 | $94,899 |
Total Patients
4,041
Total Services
23,285
Medicare Billing
$469,370
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 14 | 9,405 | $159,885 | $46,338 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 359 | 521 | $81,797 | $33,122 | 40.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 154 | 157 | $45,530 | $15,314 | 33.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 135 | 198 | $30,294 | $11,841 | 39.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 81 | 81 | $28,836 | $9,320 | 32.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 14 | 47 | $22,842 | $5,460 | 23.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 42 | 42 | $9,828 | $3,303 | 33.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 36 | $7,884 | $3,287 | 41.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 34 | $7,854 | $2,869 | 36.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $8,520 | $2,584 | 30.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 26 | 26 | $10,764 | $2,309 | 21.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 13 | 13 | $6,162 | $2,169 | 35.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 67 | 67 | $6,700 | $1,854 | 27.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 13 | 13 | $5,629 | $1,152 | 20.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 20 | 20 | $3,620 | $834.48 | 23.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 15 | $1,275 | $582.90 | 45.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 302 | 431 | $67,667 | $27,268 | 40.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 11 | 4,910 | $83,470 | $23,965 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 75 | 75 | $26,700 | $9,352 | 35.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 89 | 90 | $26,100 | $9,321 | 35.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 103 | 134 | $20,502 | $7,354 | 35.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 31 | 31 | $13,206 | $4,922 | 37.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 57 | $12,483 | $4,613 | 37.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 11 | 29 | $14,094 | $3,381 | 24.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 35 | 35 | $8,190 | $2,940 | 35.9% |
About Dr. Alan Schulman, M.D
Dr. Alan Schulman, M.D is a Neurology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992733034.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Schulman, M.D has received a total of $171,196 in payments from pharmaceutical and medical device companies, with $3,098 received in 2024. These payments were reported across 1,033 transactions from 85 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($118,211).
As a Medicare-enrolled provider, Schulman has provided services to 4,041 Medicare beneficiaries, totaling 23,285 services with total Medicare billing of $469,370. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Richmond, VA
- Active Since 06/29/2006
- Last Updated 01/13/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1992733034
Products in Payments
- AUBAGIO (Drug) $68,199
- UBRELVY (Drug) $30,022
- COPAXONE (Drug) $25,624
- AJOVY (Drug) $10,180
- QULIPTA (Drug) $6,754
- AJOVY (Biological) $6,325
- OCREVUS (Biological) $1,831
- Briviact (Drug) $757.53
- Mavenclad (Biological) $605.92
- TYSABRI (Biological) $576.83
- BOTOX (Biological) $447.88
- ACTHAR (Biological) $419.74
- Aimovig (Biological) $329.33
- Ocrevus (Biological) $318.06
- GOCOVRI (Drug) $311.26
- NURTEC ODT (Drug) $298.98
- ULTOMIRIS (Biological) $293.00
- LEMTRADA (Drug) $291.21
- KESIMPTA (Drug) $261.76
- LINQ II (Device) $258.47
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Richmond
Catherine Ham, Md, MD
Neurology — Payments: $551,939
Neurology $551,939
Dr. Daniel Hardy, M.d, M.D
Neurology — Payments: $360,216
Neurology $360,216
Myla Goldman, Md, MD
Neurology — Payments: $211,301
Neurology $211,301
Dr. Warren Felton, M.d, M.D
Neurology — Payments: $108,879
Neurology $108,879
Dr. Matthew Boyce, M.d, M.D
Neurology — Payments: $103,206
Neurology $103,206
John Wittman, M.d, M.D
Neurology — Payments: $96,999
Neurology $96,999